These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Proton MR spectroscopy of delayed cerebral radiation in monkeys and humans after brachytherapy. Kinoshita K; Tada E; Matsumoto K; Asari S; Ohmoto T; Itoh T AJNR Am J Neuroradiol; 1997 Oct; 18(9):1753-61. PubMed ID: 9367328 [TBL] [Abstract][Full Text] [Related]
23. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. Kinoshita Y; Yokota A NMR Biomed; 1997 Jan; 10(1):2-12. PubMed ID: 9251109 [TBL] [Abstract][Full Text] [Related]
24. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors. Qi ZH; Li CF; Li ZF; Zhang K; Wang Q; Yu DX Chin Med J (Engl); 2009 Jan; 122(1):39-43. PubMed ID: 19187615 [TBL] [Abstract][Full Text] [Related]
25. Discrimination between neoplastic and nonneoplastic brain lesions by use of proton MR spectroscopy: the limits of accuracy with a logistic regression model. Butzen J; Prost R; Chetty V; Donahue K; Neppl R; Bowen W; Li SJ; Haughton V; Mark L; Kim T; Mueller W; Meyer G; Krouwer H; Rand S AJNR Am J Neuroradiol; 2000 Aug; 21(7):1213-9. PubMed ID: 10954271 [TBL] [Abstract][Full Text] [Related]
26. Brain stem involvement in children with neurofibromatosis type 1: role of magnetic resonance imaging and spectroscopy in the distinction from diffuse pontine glioma. Broniscer A; Gajjar A; Bhargava R; Langston JW; Heideman R; Jones D; Kun LE; Taylor J Neurosurgery; 1997 Feb; 40(2):331-7; discussion 337-8. PubMed ID: 9007866 [TBL] [Abstract][Full Text] [Related]
27. Proton (1H) MR spectroscopy for routine diagnostic evaluation of brain lesions. Burtscher IM; Ståhlberg F; Holtås S Acta Radiol; 1997 Nov; 38(6):953-60. PubMed ID: 9394648 [TBL] [Abstract][Full Text] [Related]
28. Proton magnetic resonance spectroscopy and diffusion-weighted imaging in intracranial cystic mass lesions. Lai PH; Hsu SS; Ding SW; Ko CW; Fu JH; Weng MJ; Yeh LR; Wu MT; Liang HL; Chen CK; Pan HB Surg Neurol; 2007; 68 Suppl 1():S25-36. PubMed ID: 17963918 [TBL] [Abstract][Full Text] [Related]
29. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. Zeng QS; Li CF; Zhang K; Liu H; Kang XS; Zhen JH J Neurooncol; 2007 Aug; 84(1):63-9. PubMed ID: 17619225 [TBL] [Abstract][Full Text] [Related]
30. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Preul MC; Caramanos Z; Villemure JG; Shenouda G; LeBlanc R; Langleben A; Arnold DL Neurosurgery; 2000 Feb; 46(2):306-18. PubMed ID: 10690719 [TBL] [Abstract][Full Text] [Related]
32. Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study. Morana G; Piccardo A; Puntoni M; Nozza P; Cama A; Raso A; Mascelli S; Massollo M; Milanaccio C; Garrè ML; Rossi A Neuro Oncol; 2015 Dec; 17(12):1637-47. PubMed ID: 26405202 [TBL] [Abstract][Full Text] [Related]
33. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Rock JP; Hearshen D; Scarpace L; Croteau D; Gutierrez J; Fisher JL; Rosenblum ML; Mikkelsen T Neurosurgery; 2002 Oct; 51(4):912-9; discussion 919-20. PubMed ID: 12234397 [TBL] [Abstract][Full Text] [Related]
34. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Rabinov JD; Lee PL; Barker FG; Louis DN; Harsh GR; Cosgrove GR; Chiocca EA; Thornton AF; Loeffler JS; Henson JW; Gonzalez RG Radiology; 2002 Dec; 225(3):871-9. PubMed ID: 12461273 [TBL] [Abstract][Full Text] [Related]
35. Differentiating diffuse World Health Organization grade II and IV astrocytomas with ex vivo magnetic resonance spectroscopy. Vettukattil R; Gulati M; Sjøbakk TE; Jakola AS; Kvernmo NA; Torp SH; Bathen TF; Gulati S; Gribbestad IS Neurosurgery; 2013 Feb; 72(2):186-95; discussion 195. PubMed ID: 23147779 [TBL] [Abstract][Full Text] [Related]
36. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. Sugahara T; Korogi Y; Tomiguchi S; Shigematsu Y; Ikushima I; Kira T; Liang L; Ushio Y; Takahashi M AJNR Am J Neuroradiol; 2000 May; 21(5):901-9. PubMed ID: 10815666 [TBL] [Abstract][Full Text] [Related]
37. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. Weybright P; Sundgren PC; Maly P; Hassan DG; Nan B; Rohrer S; Junck L AJR Am J Roentgenol; 2005 Dec; 185(6):1471-6. PubMed ID: 16304000 [TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance spectroscopy detection of high lipid levels in intraaxial tumors without central necrosis: a characteristic of malignant lymphoma. Yamasaki F; Takayasu T; Nosaka R; Amatya VJ; Doskaliyev A; Akiyama Y; Tominaga A; Takeshima Y; Sugiyama K; Kurisu K J Neurosurg; 2015 Jun; 122(6):1370-9. PubMed ID: 25748300 [TBL] [Abstract][Full Text] [Related]
39. Brain magnetic resonance spectroscopy to differentiate recurrent neoplasm from radiation necrosis: A systematic review and meta-analysis. Aseel A; McCarthy P; Mohammed A J Neuroimaging; 2023 Mar; 33(2):189-201. PubMed ID: 36631883 [TBL] [Abstract][Full Text] [Related]
40. MR spectroscopy in the evaluation of recurrent contrast-enhancing lesions in the posterior fossa after tumor treatment. Weybright P; Maly P; Gomez-Hassan D; Blaesing C; Sundgren PC Neuroradiology; 2004 Jul; 46(7):541-9. PubMed ID: 15105980 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]